DUBLIN, June 9, 2022 /PRNewswire/ -- The "Investor Series: Opportunities in the Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.
The report provides detailed information on the cell and gene therapy industry, covering both core and peripheral products, and affiliated services.
It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data.
Contemporary medical science has traced thousands of clinical conditions to a genetic cause. Cancer, a life-threatening disease, also has genetic origins, and is considered among the leading causes of death across the globe. In fact, the World Health Organization (WHO) has reported that close to 10 million cancer related deaths annually, across the world.
Moreover, experts believe that there are over 7,000 different types of rare diseases (including some rare forms of cancer), most of which originate as a consequence of genetic anomalies. The majority of the aforementioned conditions are still considered incurable. As a result, these disease areas are characterized by a significant unmet need for curative interventions; and therefore, considered among the most lucrative opportunity areas for biopharmaceutical developers.
For example, ZOLGENSMA, a blockbuster product developed by Novartis, and indicated for the treatment of spinal muscular atrophy, generated net revenues of approximately USD 1.35 billion in 2021 alone. The first gene therapy trial was conducted in 1990, and it took almost three decades for the first of such interventions to enter the market.
Given recent developments in genetic manipulation, cell biology and molecular targeting, a number of highly specific interventions have been developed against prominent types of cancers and certain rare genetic conditions. Currently, there are over 20 cell and gene therapies approved for use in the United States alone.
During the COVID-19 pandemic, the pace of R&D in this field slowed down - a consequence of complex manufacturing protocols, extensive logistical considerations and supply chain-related concerns. However, the field still witnessed a considerable inflow of capital, with over USD 21 billion invested into various companies since the start of the pandemic.
With over 1,200 product candidates in various stages of development, experts suggest that, by 2025, the US FDA may start approving around 10 to 20 cell and gene therapy products, on an annual basis. It is likely that, over the next two decades, gene therapies facilitate the evolution of medical practice from a treatment-based paradigm to a prevention-focused approach.
Despite the fact that niche startups are spearheading the innovation in this domain, several big pharma players are also actively acquiring capabilities related to upcoming advanced therapy medical products (ATMPs). Prominent players in the field, such as Juno Therapeutics, AveXis, and Kite Pharma, have been acquired as a consequence of the rapid expertise building efforts of more established pharma companies.
Moreover, gene therapy-focused businesses that have gone public, have experienced considerable growth in share value as their respective products / product candidate progressed through the various stages of development. Taking into consideration both the historical and contemporary scenario, the cell and gene therapies market continues to present lucrative investment opportunities for both short- and long-term investors.
Key Topics Covered:
Excel Deliverable
1. Key Innovators & Products Dataset
2. Funding & Investments Analysis
3. Company Valuation Analysis
4. Fundamental & Technical Financial Analysis
5. Business Risk Analysis
6. Market Forecast & Opportunity Analysis
7. Returns on Investment
PowerPoint Deliverable
1. Context
2. Project Approach
3. Project Objectives
4. Executive Summary
Section I: Need for Cell and Gene Therapy & Key Innovators Landscape
5. The Cell and Gene Therapy Market
6. Key Innovators Competitive Landscape
7. Products Landscape & Company Health Indexing
8. Value Proposition Analysis
9. Company Competitiveness Analysis
Section II Analysis of Investments & Company Valuation
10. Funding and Investments Analysis
11. Company Valuation Analysis
Section III Financial Analysis & Assessment of Business Risks
12. Financial Analysis of Public Ventures
13. Business Risk Analysis
Section IV Market Forecast & Opportunity Analysis
14. Market Forecast and Opportunity Analysis
Section V Analysis of Returns on Investment & Key Acquisition Targets
15. Analysis of Returns on Investment
16. Key Acquisition Targets
17. Conclusion
18. Appendices
For more information about this report visit https://www.researchandmarkets.com/r/f8cqbx
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article